Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia by Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock

“…**Objectives:** This study assessed the comparative rates of treatment interruption and regimen change between patients initiating first-line therapy with a first-generation tyrosine kinase inhibitor (1GTKI) imatinib versus second-generation TKI (2GTKI), dasatinib or nilotinib, for the treatment of CML in clinical practice. …”
Get full text

Contralateral Renal Cell Carcinoma Ureteric Metastases Can Arise on Tyrosine Kinase Adjuvant Therapy and Be Effectively Treated by Endoscopic Laser Excision and Ablation by Sarah L. Reid, Nikolas J. Arestis, Craig McIlhenny, Gavin W. A. Lamb

Get full text

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs) by Qingjian He, Junling Lin, Chanjuan Mo, Guodong Li, Jianzhong Lu, Qiyin Sun, Lijun Cao, Haojian Gan, Quan Sun, Jiafang Yao, Shengyi Lian, WenJuan Wang

Subjects: Get full text

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor by T. D. de Gruijl, G. Giaccone, R. J. Scheper, H. van Cruijsen, K. Hoekman, B. C. Kuenen, A. J. M. van den Eertwegh, A. G. M. Stam

Get full text

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia or Philadelphia chromosome‐like acute lymphoblastic leukemia by Xiaoxia Wu, Shenqi Lu, Xinhui Zhang, Zhen Yang, Aining Sun, Depei Wu, Huifen Zhou, Miao Miao

Subjects: Get full text

The Lck Paradox: Because of Inconsistent Experimental Evidence, the Role of the Protein Tyrosine Kinase p56lck in Early Thymic Development Remains Poorly Defined by Klaus Eichmann

Get full text

Deep learning-based CT radiomics predicts prognosis of unresectable hepatocellular carcinoma treated with TACE-HAIC combined with PD-1 inhibitors and tyrosine kinase inhibitors by Linan Yin, Ruibao Liu, Wei Li, Shijie Li, Xunbo Hou

“…Abstract Objective To develop and validate a computed tomography (CT)-based deep learning radiomics model to predict treatment response and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) treated with transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors and tyrosine kinase inhibitors (TKIs). Methods This retrospective study included 172 patients with uHCC who underwent combination therapy of TACE-HAIC with TKIs and PD-1 inhibitors. …”
Get full text

Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1α Inhibitor) and Dasatinib (A Second-Generation Tyrosine Kinase Inhibitor) on Chronic Myelocytic Leukemia Cells by Yuexian Zhang, Heng Chen, Yunfeng Shen, Xin Zhou

Get full text

Long‐term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14‐year, single‐center experience by Jwa Hoon Kim, Min‐Hee Ryu, Changhoon Yoo, Heejung Chae, Hana Na, Moyoul Beck, Beom Su Kim, Moon‐Won Yoo, Jeong Hwan Yook, Byung Sik Kim, Ki‐Hun Kim, Chan Wook Kim, Yoon‐Koo Kang

“…Abstract The long‐term effects of tyrosine kinase inhibitors (TKIs), including imatinib, and surgical intervention on advanced gastrointestinal stromal tumor (GIST) were evaluated. …”
Get full text

Vitamin K‐dependent gamma‐carboxyglutamic acid protein 1 promotes pancreatic ductal adenocarcinoma progression through stabilizing oncoprotein KRAS and tyrosine kinase receptor EGFR by Zheng Wu, Qing Ye, Shan Zhang, Li‐Peng Hu, Xiao‐Qi Wang, Lin‐Li Yao, Lei Zhu, Shu‐Yu Xiao, Zong‐Hao Duan, Xue‐Li Zhang, Shu‐Heng Jiang, Zhi‐Gang Zhang, De‐Jun Liu, Dong‐Xue Li, Xiao‐Mei Yang

Get full text

Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature by Siobhan S. Pattwell, Eric Q. Konnick, Yajuan J. Liu, Rebecca A. Yoda, Laligam N. Sekhar, Patrick J. Cimino

Get full text

A Simple Machine Learning-Based Quantitative Structure–Activity Relationship Model for Predicting pIC₅₀ Inhibition Values of FLT3 Tyrosine Kinase by Jackson J. Alcázar, Ignacio Sánchez, Cristian Merino, Bruno Monasterio, Gaspar Sajuria, Diego Miranda, Felipe Díaz, Paola R. Campodónico

“…<b>Background/Objectives:</b> Acute myeloid leukemia (AML) presents significant therapeutic challenges, particularly in cases driven by mutations in the FLT3 tyrosine kinase. This study aimed to develop a robust and user-friendly machine learning-based quantitative structure–activity relationship (QSAR) model to predict the inhibitory potency (pIC₅₀ values) of FLT3 inhibitors, addressing the limitations of previous models in dataset size, diversity, and predictive accuracy. …”
Get full text

Effects of Food on the Pharmacokinetics and Safety of HA121-28 Tablet, a Novel Multi-Targeting Tyrosine Kinase Inhibitor, in Healthy Chinese Subjects: A Phase I Clinical Trial by Liu Y, Li X, Zhang M, Men Y, Wang Y, Zhu X, Zheng L

Subjects: Get full text

REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION by Ivan Tonev, Chavdar Botev, Georgui Balatzenko, Milcho Mincheff

“…The mother achieved hematologic, cytogenetic and molecular remission within the next 6-9 months after initiation of tyrosine kinase inhibitor therapy. Discussion: The classical treatment for CML includes tyrosine kinase inhibitors, chemotherapy and/or allogeneic haematopoietic stem cell transplantation. …”
Get full text

Perbedaan Rerata Kadar Soluble Fms-Like Tyrosine Kinase-1 (Sflt-1) Serum pada Penderita Early Onset, Late Onset Preeklampsia Berat / Eklampsia dan Kehamilan Normal by Laila Rahmi, Rahmatina B. Herman, Yusrawati .

“…Kegagalan pengaturan dan ketidakseimbangan agen vasoaktif proangiogenik dan antiangiogenik plasenta, <em>soluble fms</em><em>-like tyrosine kinase</em>-1 (sFlt-1), <em>vascular endothelial growth factor</em> (VEGF) dan <em>placental growth factor</em> (PlGF) memainkan peran penting dalam patogenesis preeklampsia. …”
Get full text

Comparison of glycosylated fibronectin versus soluble fms-like tyrosine kinase/placental growth factor ratio testing for the assessment of pre-eclampsia: protocol for a multicentre diagnostic test accuracy study by Marcus Green, Chao Wang, Sarah Fisher, Amarnath Bhide, Ramesh Ganapathy, Basky Thilaganathan, Nouran Elbarbary

“…This study aimed to test the hypothesis that the sensitivity of the GlyFn test is not inferior to that of the current gold standard of soluble fms-like tyrosine kinase (sFlt)/PlGF-based laboratory testing for pre-eclampsia.Methods and analysis This is a multicentre prospective study. …”
Get full text

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group by Ugo Giordano, Agnieszka Piekarska, Witold Prejzner, Lidia Gil, Jan Maciej Zaucha, Joanna Kujawska, Zuzanna Dybko, Krzysztof Dudek, Sebastian Giebel, Jarosław Dybko

Subjects: Get full text

Different Activity of the Biological Axis VEGF-Flt-1 (fms-Like Tyrosine Kinase 1) and CXC Chemokines between Pulmonary Sarcoidosis and Idiopathic Pulmonary Fibrosis: A Bronchoalveolar Lavage Study by Katerina M. Antoniou, Giannoula Soufla, Athanasia Proklou, George Margaritopoulos, Christiana Choulaki, Rena Lymbouridou, Katerina D. Samara, Demetrios A. Spandidos, Nikolaos M. Siafakas

“…We estimated the levels of vascular endothelial growth factor (VEGF) and its high-affinity receptor, Flt-1 (fms-like tyrosine kinase 1), in bronchoalveolar lavage fluid (BALF) of patients with IPF and pulmonary sarcoidosis. …”
Get full text

Ibrutinib-associated osteonecrosis of the jaw by Annu Singh, Sion Na, Joseph M. Huryn, Cherry L. Estilo, Steven Horwitz, SaeHee K. Yom

Subjects: Get full text

Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report by Yukihiro Umeda, Satomi Kimura, Junya Kimura, Yoshiaki Imamura, Tamotsu Ishizuka

Subjects: Get full text